See important safety information, including boxed warning, in the attached prescribing information.

The use of tirzepatide in patients undergoing surgical procedures or hospitalization has not been evaluated.

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1

Health care providers should use patient medical records and their clinical judgement to make a treatment recommendation. The additional considerations below may be helpful to determine what is best for their patient (Pharmacokinetics and Pharmacodynamics, Drug Interactions, Precautions).

Administer tirzepatide

• once weekly
• any time of day, and
• with or without food.1

Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm.1

Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours.1

Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once-weekly administration.1

Tirzepatide is highly bound to plasma albumin (99%).1

The elimination half-life of tirzepatide is approximately 5 days.1

For full information on pharmacokinetics, please refer to the enclosed prescribing information.1 

Because tirzepatide delays gastric emptying, it could potentially impact the absorption of concomitantly administered oral medications. The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.1

Patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (eg, warfarin) should be monitored when concomitantly administered with tirzepatide.1

In vitro studies of tirzepatide showed low potential to inhibit or induce CYP enzymes, and to inhibit drug transporters.1

Following first dose of tirzepatide 5 mg, acetaminophen maximum concentration (C_max) was reduced by 50% and the median peak plasma concentration (t_max) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen C_max and t_max. Overall acetaminophen exposure (AUC_0-24h) was not influenced.1

For full information on drug interactions, please refer to the enclosed prescribing information.1 

Tirzepatide should not be used in patients with a

• personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), or
• known serious hypersensitivity to tirzepatide or any of the excipients in tirzepatide. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide.1

Tirzepatide should be discontinued if pancreatitis is suspected.1

Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.1

Use of tirzepatide may be associated with gastrointestinal adverse reactions, sometimes severe. Tirzepatide has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which if severe could cause acute kidney injury.1

For full information on precautions, please refer to the enclosed prescribing information.1 

MOUNJARO® (tirzepatide) injection, for subcutaneous use, Lilly